

2008 ACC/AHA STEMI/NSTEMI Performance Measures: Inpatient Measure Descriptions

Measure Name	Measure Description
Performance measures	
1. Aspirin at arrival	AMI patients who received aspirin within 24 h before or after hospital arrival
2. Aspirin prescribed at discharge	AMI patients who are prescribed aspirin at hospital discharge
3. Beta-blocker prescribed at discharge	AMI patients who are prescribed a beta-blocker at hospital discharge
4. Statin at discharge	AMI patients who are prescribed a statin at hospital discharge
5. Evaluation of LVSF [†]	AMI patients with documentation in the hospital record that LVSF was evaluated during hospitalization or is planned after discharge
6. ACEI or ARB for LVSD	AMI patients with LVSD who are prescribed an ACEI or ARB at hospital discharge (for purposes of this measure, LVSD is defined as chart documentation of an LVEF less than 40% or a narrative description of LVSF consistent with moderate or severe systolic dysfunction)
7. Time to fibrinolytic therapy	Median time from hospital arrival to administration of fibrinolytic therapy in AMI patients with ST-segment elevation or LBBB on the ECG performed closest to hospital arrival time; AMI patients with ST-segment elevation or LBBB on the ECG closest to hospital arrival time receiving fibrinolytic therapy during the hospital stay with a time from hospital arrival to fibrinolysis of 30 min or less
8. Time to PCI	Median time from hospital arrival to primary PCI in AMI patients with ST-segment elevation or LBBB on the ECG performed closest to arrival time; AMI patients with ST-segment elevation or LBBB on the ECG closest to hospital arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 min or less
9. Reperfusion therapy	AMI patients with ST-segment elevation or LBBB on the ECG performed closest to arrival receiving either fibrinolysis or primary PCI or who are transferred to another facility for primary PCI
10. Time from ED arrival at STEMI referral facility to ED discharge from STEMI referral facility in patients transferred for primary PCI [†]	Median time from ED arrival at STEMI referral facility to ED discharge from STEMI referral facility for AMI patients with ST-segment elevation or LBBB on the ECG performed closest to hospital arrival time who are transferred to a STEMI receiving facility for primary PCI
11. Time from ED arrival at STEMI referral facility to primary PCI at STEMI receiving facility among transferred patients [†]	Median time from patient arrival at a STEMI referral facility's ED to time of primary PCI at a STEMI receiving facility for AMI patients presenting with ST-segment elevation or LBBB on the ECG performed closest to first hospital arrival time who are transferred to a STEMI receiving facility for primary PCI
12. Adult smoking cessation advice/counseling	AMI patients with a history of smoking cigarettes who are given smoking cessation advice or counseling during hospital stay
13. Cardiac rehabilitation patient referral from an inpatient setting ^{†6}	All patients hospitalized with a primary diagnosis of AMI referred to an early outpatient CR program
Test measures*	
T-1. LDL cholesterol assessment	AMI patients with documentation of LDL cholesterol level in the hospital record or documentation that LDL cholesterol testing was done during the hospital stay or is planned after discharge
T-2. Excessive initial heparin dose [†]	AMI patients who receive excess dosing of UFH initially
T-3. Excessive initial enoxaparin dose [†]	AMI patients who receive excess dosing of subcutaneous enoxaparin initially
T-4. Excessive initial abciximab dose [†]	AMI patients who receive excess dosing of abciximab initially
T-5. Excessive initial eptifibatide dose [†]	AMI patients who receive excess dosing of eptifibatide initially
T-6. Excessive initial tirofiban dose [†]	AMI patients who receive excess dosing of tirofiban initially
T-7. Anticoagulant dosing protocol [†]	Presence of a protocol or other clinical aid (eg, nomogram, electronic order entry) in the hospital record of AMI patients that addresses dosing of anticoagulant therapy and parenteral antiplatelet therapy (ie, UFH, low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors)
T-8. Anticoagulant error tracking system [†]	Evidence of a tracking system for identifying dosing errors in anticoagulation therapy in the hospital record of AMI patients.
T-9. Clopidogrel prescribed at discharge for medically treated AMI patients [†]	Medically treated AMI patients who are prescribed clopidogrel or ticlopidine at hospital discharge

LVEF indicates left ventricular ejection fraction; LBBB, left bundle-branch block; ECG, electrocardiographic; ED, emergency department; CR, cardiac rehabilitation/secondary prevention; and UFH, unfractionated heparin.

*Test measures have been designated for use in internal quality improvement programs only and are not appropriate for any other use, eg, pay for performance, physician ranking, or public reporting programs.

[†]New measures.

(*Circulation*. 2008;118:2596-2648.)

2008 ACC/AHA STEMI/NSTEMI Performance Measurement Set: Dimensions of Care Inpatient Measures Matrix

Measure Name	Diagnostics	Patient Education	Treatment	Self-Management*	Monitoring of Disease Status*
Performance measures					
1. Aspirin at arrival			✓		
2. Aspirin prescribed at discharge			✓		
3. Beta-blocker prescribed at discharge			✓		
4. Statin prescribed at discharge			✓		
5. Evaluation of LVSF	✓				
6. ACEI or ARB for LVSD			✓		
7. Time to fibrinolytic therapy			✓		
8. Time to primary PCI			✓		
9. Reperfusion therapy			✓		
10. Time from ED arrival at STEMI referral facility to ED discharge from STEMI referral facility in patients transferred for primary PCI			✓		
11. Time from ED arrival at STEMI referral facility to primary PCI at STEMI receiving facility among transferred patients			✓		
12. Adult smoking cessation advice/counseling		✓			
13. Cardiac rehabilitation patient referral from an inpatient setting ⁶		✓	✓		
Test measures					
T-1. LDL cholesterol assessment	✓				
T-2. Excessive initial heparin dose			✓		
T-3. Excessive initial enoxaparin dose			✓		
T-4. Excessive initial abciximab dose			✓		
T-5. Excessive initial eptifibatide dose			✓		
T-6. Excessive initial tirofiban dose			✓		
T-7. Anticoagulant dosing protocol (structural measure)			✓		
T-8. Anticoagulant error tracking system (structural measure)			✓		
T-9. Clopidogrel prescribed at discharge for medically treated AMI patients			✓		
ED indicates emergency department.					
*Although no current measures exist for these dimensions of care for the inpatient setting, future measure development efforts will examine how to address this gap in the measurement set.					